Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Study Examining the Combination of Lenalidomide and Azacitidine for Relapsed/Refractory CLL and SLL

This study has been terminated.
(anticipated results not seen and population not seen)
Celgene Corporation
Information provided by (Responsible Party):
Hackensack University Medical Center Identifier:
First received: November 15, 2010
Last updated: November 7, 2012
Last verified: November 2012
No Study Results Posted on for this Study
  Study Status: This study has been terminated.
  Study Completion Date: October 2011
  Primary Completion Date: October 2011 (Final data collection date for primary outcome measure)